Sources and Guidelines Referenced

The clinical guidance in this explainer is drawn from consensus recommendations and published evidence from major medical societies: European Association for the Study of the Liver (EASL Clinical Practice Guidelines, 2018), American Association for the Study of Liver Diseases (AASLD Practice Guidance, 2023), National Comprehensive Cancer Network (NCCN Guidelines for Hepatobiliary Cancers, v1.2024), Cardiovascular and Interventional Radiological Society of Europe (CIRSE Standards of Practice, 2021), and pivotal clinical trials including Llovet et al. (Lancet, 2002), Salem et al. (LEGACY Trial, Hepatology, 2021), and the DOSISPHERE-01 Trial (Garin et al., Lancet Gastroenterology & Hepatology, 2021).

Interventional Radiology: TACE and Y-90 Radioembolization for Liver Tumors: A Comprehensive Patient Guide

1. Definition and Medical Identity

Transarterial chemoembolization (TACE) and Yttrium-90 radioembolization (Y-90 or TARE) are image-guided, catheter-based treatments for primary and secondary liver tumors. Performed by interventional radiologists, these minimally invasive procedures deliver concentrated anti-cancer drugs or radioactive particles directly through the liver's arterial network to kill tumor cells while preserving healthy organ tissue.

These procedures belong to the field of interventional oncology, a subspecialty that uses medical imaging to perform precise, targeted cancer therapies without open surgery. Synonyms and related clinical terms include transarterial radioembolization (TARE), selective internal radiation therapy (SIRT), conventional TACE (cTACE), and drug-eluting bead TACE (DEB-TACE). The primary clinical goal of these therapies is local tumor control, prolonging survival, downstaging tumors for surgical removal, or bridging patients who are awaiting a liver transplant.

2. The Underlying Condition or Need

The liver is the primary site for hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and a frequent location for metastatic disease from colorectal, neuroendocrine, and pancreatic cancers. The underlying biological problem in liver cancer is uninhibited cellular multiplication that compromises normal liver function, disrupts vascular structures, and eventually spreads to other organs.

Patients with primary liver cancer frequently have underlying cirrhosis (severe liver scarring) caused by chronic hepatitis B or C infection, alcohol-associated liver disease, or metabolic dysfunction-associated steatohepatitis (MASH). Symptoms often remain hidden in early stages, appearing later as right upper quadrant abdominal pain, unexplained weight loss, jaundice (yellowing of the skin and eyes), ascites (fluid accumulation in the abdomen), or worsening liver function tests. Left untreated, primary and secondary liver cancers progress rapidly, causing liver failure, internal bleeding, or systemic tumor spread. Transarterial therapies intervene when surgical removal is unsafe due to tumor location or underlying liver disease.

3. How the Treatment Works — Mechanism

Transarterial therapies exploit the dual blood supply of the human liver. Normal liver tissue receives approximately 75% of its blood flow from the portal vein and only 25% from the hepatic artery. In contrast, malignant liver tumors derive over 80% to 90% of their blood supply from branches of the hepatic artery.

By inserting a thin tube called a microcatheter through the vascular system into the specific hepatic artery branches supplying a tumor, clinicians deliver targeted therapeutic agents directly into the cancer. In TACE, a high concentration of chemotherapeutic drugs (such as doxorubicin or cisplatin) is injected, followed by tiny synthetic particles that physically block or embolize the blood vessels. This dual mechanism induces severe tumor cell toxicity while starving the tumor of oxygen and nutrients (ischemia). The vascular blockage also traps the chemotherapy inside the tumor, increasing local drug exposure while minimizing systemic side effects throughout the rest of the body.

In Y-90 radioembolization, millions of microscopic glass or resin spheres embedded with the radioactive isotope Yttrium-90 are injected into the tumor-feeding vessels. Yttrium-90 releases high-energy beta radiation over a short distance (average path length of 2.5 millimeters in tissue), damaging tumor cell DNA and causing cell death. Because the spheres are tiny, Y-90 works predominantly through localized radiation (radiotherapy) rather than complete vessel blockage, keeping blood flowing through the microvasculature to deliver oxygen that enhances radiation sensitivity.

4. Types and Variations

Transarterial liver therapies encompass several distinct technical approaches, selected based on tumor size, vascular structure, underlying liver function, and overall patient health. The main types include conventional TACE, drug-eluting bead TACE, and Y-90 radioembolization using glass or resin microspheres.

Clinicians determine the optimal variation through multidisciplinary tumor board review. Key decision factors include the patient's liver functional reserve measured by the Child-Pugh score, the presence of blood clots in the portal vein (portal vein thrombosis), tumor size, and whether the primary goal is rapid tumor destruction, long-term disease control, or preparing the patient for surgery.

5. Who the Treatment Is For — Indications

Transarterial therapies are indicated for patients with primary or secondary liver malignancies that cannot be surgically removed or treated with thermal ablation, provided liver function remains adequate. Key indications defined by the EASL 2018 and AASLD 2023 guidelines include:

• Barcelona Clinic Liver Cancer (BCLC) Intermediate Stage (B) HCC: Patients with multiple liver tumors, no spread outside the liver, no main portal vein invasion, and preserved liver function (Child-Pugh Class A or well-compensated Class B).
• Bridging Therapy to Liver Transplantation: Patients within Milan criteria (one tumor up to 5 cm, or up to 3 tumors each up to 3 cm) who face waiting times over 6 months, to prevent tumor growth beyond transplant eligibility limits.
• Downstaging to Curative Therapies: Patients with liver tumors exceeding standard transplant or surgical resection criteria, aimed at shrinking lesions to meet safety requirements.
• Advanced HCC with Portal Vein Invasion: Select patients with segmental or branch portal vein tumor thrombosis, where Y-90 radioembolization is preferred due to its low embolic risk (Salem et al., 2016).
• Unresectable Intrahepatic Cholangiocarcinoma: Inoperable bile duct tumors within the liver, either as primary therapy or combined with systemic chemotherapy.
• Chemotherapy-Refractory Liver Metastases: Liver-dominant metastatic spread from colorectal carcinoma, neuroendocrine tumors, uveal melanoma, or breast cancer that has progressed on standard systemic drugs.

6. Who the Treatment Is NOT For — Contraindications

Certain patient characteristics and anatomical factors make transarterial liver therapies unsafe due to a high risk of life-threatening liver failure or non-target organ damage.

Absolute Contraindications

• Decompensated Liver Failure: Child-Pugh Class C status, bilirubin greater than 3.0 mg/dL, severe ascites, or hepatic encephalopathy.
• Main Portal Vein Occlusion: Complete blockage of the main portal vein trunk without adequate collateral blood flow (absolute contraindication for TACE; relative for Y-90).
• Excessive Lung Shunting (for Y-90): Vascular shunting to the lungs resulting in an estimated cumulative radiation dose to the lungs exceeding 30 Gray (Gy) in a single infusion or 50 Gy lifetime limit.
• Irreversible Flow to Gastrointestinal Organs: Inability to prevent Y-90 or embolic microspheres from flowing into arteries supplying the stomach, duodenum, or pancreas during pre-procedure mapping angiogram.
• Severe Renal Impairment or Severe Allergy: Advanced kidney dysfunction (eGFR < 30 mL/min/1.73m²) or severe contrast allergy that cannot be managed with medication.

Relative Contraindications

• Moderate liver impairment (Child-Pugh score 8–9).
• Extensive tumor burden replacing more than 50% to 70% of total liver volume.
• Untreated gastroesophageal varices at high risk of bleeding.
• Recent gastrointestinal bleeding or uncorrectable bleeding disorders (platelet count < 50,000/µL or INR > 1.5).

7. Alternatives and Clinical Comparison

Choosing between TACE, Y-90, surgical therapies, thermal ablation, and systemic treatments depends on tumor stage, location, liver health, and overall patient performance status.

As highlighted in current NCCN guidelines (v1.2024), Y-90 radioembolization is increasingly favored over TACE for patients with large single tumors (> 5 cm), those needing a bridge to liver transplantation, or patients with branch portal vein tumor invasion, as radioembolization produces longer time-to-progression and fewer hospital readmissions (Salem et al., LEGACY Trial, 2021).

8. Pre-Treatment Phase

The pre-treatment phase ensures patient safety, maps vascular anatomy, and confirms that liver function can tolerate the procedure.

Initial Evaluation and Diagnostics

Patients undergo a baseline clinical history, physical exam, and assessment of performance status using the Eastern Cooperative Oncology Group (ECOG) scale. Baseline blood tests evaluate liver function (total bilirubin, serum albumin, prothrombin time/INR, AST, ALT, alkaline phosphatase), renal function (creatinine, blood urea nitrogen), complete blood count (platelets, hemoglobin, white blood cells), and tumor markers (Alpha-Fetoprotein [AFP] for HCC, or CEA and CA19-9 for colorectal/cholangiocarcinoma metastases). Multiphasic cross-sectional imaging—specifically dynamic contrast-enhanced MRI or triphasic liver CT—is mandatory to map tumor number, size, vascularity, and arterial supply.

Y-90 Treatment Planning (Mapping Angiography)

Unlike TACE, Y-90 radioembolization requires a mandatory diagnostic planning procedure 1 to 2 weeks before actual therapy:

• Diagnostic Angiography: An interventional radiologist inserts a catheter into the liver arteries to map blood vessels and coil-occlude (block) any small arterial branches leading to the stomach or intestines to protect them from unintended radiation.
• Technetium-99m MAA Injection: A small test radioactive tracer, Technetium-99m macroaggregated albumin (99mTc-MAA), is injected into the liver artery to mimic Y-90 microspheres.
• SPECT/CT Nuclear Scanning: The patient undergoes gamma camera imaging to calculate the fraction of blood shunting from the liver to the lungs (lung shunt fraction) and verify that radioactive particles will not enter gastrointestinal organs.
• Dosimetry Calculation: Medical physicists calculate the exact gigabecquerel (GBQ) radiation dose required to treat the tumor while keeping normal liver tissue safe (Garin et al., DOSISPHERE-01 Trial, 2021).

9. The Procedure — Step-by-Step Clinical Detail

Transarterial procedures are performed in a specialized interventional radiology angiosuite under strict sterile conditions with continuous heart, blood pressure, and oxygen monitoring.

Step 1: Patient Preparation and Vascular Access

The patient lies flat on the fluoroscopy table and receives intravenous conscious sedation and anti-nausea medications. The groin (femoral artery) or wrist (radial artery) is disinfected and numbed with local anesthetic. Using ultrasound guidance, a small needle punctures the artery, and a thin tube called an arterial sheath is inserted.

Step 2: Selective Angiography

A small catheter is guided over a wire under fluoroscopic X-ray visualization into the main trunk of the hepatic artery. Radiopaque contrast dye is injected while acquiring rapid X-ray images (digital subtraction angiography) to identify the specific feeder arteries supplying the tumor.

Step 3: Microcatheter Cannulation

A microcatheter (diameter less than 1 millimeter) is carefully threaded through the primary catheter directly into the subsegmental or segmental arterial branches feeding the tumor, preserving blood flow to normal liver tissue wherever possible.

Step 4: Agent Delivery

• For Conventional TACE: Chemotherapy (such as doxorubicin, cisplatin, or mitomycin C) emulsified in lipiodol is infused under direct X-ray visualization, followed by gel-foam or synthetic microspheres until blood flow in the feeding vessel slows to a complete stop.
• For DEB-TACE: Drug-eluting beads pre-loaded with doxorubicin are infused slowly into the tumor vessels until blood flow slows.
• For Y-90 Radioembolization: The microcatheter position is re-confirmed with contrast. The pre-measured container of Y-90 glass or resin microspheres is attached to a specialized delivery system, and the radioactive microspheres are infused slowly into the tumor-supplying arteries using saline flushes.

Step 5: Completion and Closure

Follow-up contrast injections confirm complete embolization or flow distribution to the tumor while confirming that non-target vessels remain open. The catheters are removed, and the arterial puncture site is sealed using a vascular closure device or manual pressure for 15 to 20 minutes to prevent bleeding. Total procedure duration is typically 60 to 120 minutes.

10. Immediate Post-Procedure Period

Following the procedure, the patient is transferred to a post-anesthesia care unit or specialized interventional radiology recovery bay for close monitoring.

First 24 to 48 Hours

If femoral artery access was used, the patient must lie flat on their back with the access leg straight for 2 to 6 hours to ensure arterial clot stability. If radial artery access was used, bedrest is not required, and the patient can sit upright immediately while wearing a radial compression band. Vital signs, pulse checks in the treated leg or arm, and site checks for groin or wrist hematoma are performed frequently.

Patients are closely monitored for post-embolization syndrome (PES), a clinical response caused by tissue ischemia and inflammatory cytokine release. Symptoms include right upper quadrant abdominal pain, nausea, vomiting, low-grade fever (< 38.5°C / 101.3°F), and fatigue. Management involves IV fluids, intravenous or oral analgesics (such as acetaminophen or opioid pain medications), and antiemetics (such as ondansetron). Most TACE patients remain in the hospital overnight for observation and pain control, whereas many Y-90 patients can be discharged on the same day or after a short overnight stay.

11. Recovery — Short and Long Term

Recovery times vary depending on whether the patient received chemoembolization or radioembolization, as well as their underlying liver reserve.

Recovery Timeline

• Days 1–3: Acute post-embolization symptoms peak and begin to lessen. Patients transition from IV to oral pain and anti-nausea medications. Light walking is encouraged to prevent deep vein blood clots.
• Days 4–7: Fever and nausea usually resolve completely. Low-grade fatigue and mild loss of appetite may continue. Patients can resume light activities of daily living.
• Weeks 2–4: Fatigue gradually improves. Complete blood counts, renal function, and liver enzyme panels are checked to confirm hepatic recovery. Most individuals return to work and routine non-strenuous activity within 7 to 14 days.
• Month 1 to 3: Follow-up imaging (contrast-enhanced MRI or dynamic multiphase CT) is performed at 4 to 12 weeks to assess initial treatment response using specialized radiological standards, such as Modified RECIST (mRECIST) or LI-RADS response criteria.

12. Risks, Side Effects, and Complications

While transarterial therapies are less invasive than open surgery, they carry specific procedure-related, chemical, and radiation risks.

Warning Signs Requiring Urgent Medical Evaluation

Patients must seek immediate medical care if they experience severe, worsening abdominal pain unrelieved by pain medication, high fevers (> 38.5°C / 101.3°F) with chills, persistent vomiting preventing fluid intake, severe dizziness or shortness of breath, yellowing of the skin or eyes, swelling in the legs or abdomen, or active bleeding or a rapidly expanding lump at the vascular puncture site.

13. Lifestyle and Behavioural Considerations

Optimizing health before and after transarterial therapy improves liver tolerance, lowers complication risks, and supports long-term outcomes.

Pre-Procedure Optimisation

• Alcohol Abstinence: Complete abstinence from alcohol is essential to prevent added stress on liver cells and preserve liver functional reserve.
• Nutrition: Maintaining adequate protein intake (1.2 to 1.5 grams per kilogram of body weight per day) helps prevent muscle loss (sarcopenia) common in advanced liver disease.
• Medication Review: Blood thinners (anticoagulants and antiplatelets) must be stopped under medical supervision prior to arterial puncture. Nonsteroidal anti-inflammatory drugs (NSAIDs like ibuprofen or naproxen) should be avoided because they increase bleeding risk and kidney strain.

Post-Procedure Restrictions

Patients should avoid heavy lifting (> 10 lbs / 4.5 kg) and strenuous exercise for 5 to 7 days to protect the arterial puncture site. Showering is permitted after 24 to 48 hours, but soaking in baths, hot tubs, or swimming pools should be avoided until the vascular entry site is completely healed. Radiologic safety precautions after Y-90 are minimal because beta radiation travels only a short distance in tissue; however, clinical guidelines recommend avoiding prolonged close contact (within 3 feet for more than a few hours) with small children or pregnant women for the first 3 to 7 days as a precaution.

14. How Outcomes Are Measured

Treatment success in interventional oncology is evaluated using combination radiological, laboratory, and clinical measures, rather than relying solely on tumor size changes.

Radiological Response Criteria

Traditional RECIST criteria (which measure simple physical changes in tumor size) are inadequate for embolization or radiation therapies, as successful treatments kill tumor cells without immediately shrinking the overall tumor mass. Clinicians use modified evaluation systems:

• Modified RECIST (mRECIST): Measures changes in the active, contrast-enhancing portion of the tumor on dynamic CT or MRI. A complete disappearance of arterial contrast enhancement indicates a complete response (CR).
• LI-RADS Treatment Response Algorithm (TRA): Classifies treated lesions as Non-Viable, Equivocal, or Viable based on residual contrast enhancement and treatment-specific imaging features.

Biomarker and Survival Endpoints

Serum tumor marker response provides early confirmation of treatment effectiveness. A drop of more than 50% in serum alpha-fetoprotein (AFP) within 4 to 8 weeks after treatment correlates with overall survival improvements in HCC. Clinical endpoints evaluated in major research trials include time-to-progression (TTP), progression-free survival (PFS), rate of successful downstaging to transplant or surgery, and overall survival (OS).

If follow-up imaging at 1 to 3 months shows incomplete tumor death (residual viable tumor) or new tumor spots in other areas of the liver, additional planned TACE or Y-90 sessions may be performed, provided liver function remains adequate.

15. Recent Advances and Current Standard of Care

The standard of care in transarterial therapies has evolved significantly over the past decade through technical innovations, personalized treatment dosing, and combination therapies.

Personalized Dosimetry in Y-90 Radioembolization

Historically, Y-90 radioembolization used simple body surface area or fixed dose models. The landmark randomized DOSISPHERE-01 trial (Garin et al., 2021) demonstrated that tailored multi-compartmental dosimetry—aiming for a high radiation dose (≥ 205 Gy) directly to the tumor while limiting healthy liver exposure—dramatically increased objective response rates (71% vs. 36%) and significantly improved median overall survival (26.6 months vs. 10.7 months) compared to standard activity calculations.

Combination with Systemic Immunotherapy

The therapeutic landscape for hepatocellular carcinoma was reshaped by combining local transarterial therapies with systemic immune checkpoint inhibitors (such as anti-PD-1 / anti-PD-L1 antibodies) and anti-angiogenic targeted agents. Local arterial therapies trigger massive tumor cell destruction, releasing tumor antigens that stimulate the immune system. When combined with systemic immunotherapy (e.g., Atezolizumab plus Bevacizumab), this combination creates a synergistic response that attacks both the main liver tumor and microscopic cancer cells throughout the body (NCCN Guidelines, v1.2024).

Advanced Image Guidance

Modern interventional radiology suites utilize cone-beam computed tomography (CBCT) integrated directly into the X-ray equipment. CBCT generates three-dimensional, high-resolution cross-sectional images during catheterization, enabling interventional radiologists to map complex tumor blood vessels in real time, confirm microcatheter placement, and prevent non-target delivery to adjacent organs.

16. Common Myths and Misconceptions

Myth: TACE and Y-90 radioembolization are major, open abdominal surgeries.
Reality: These procedures are minimally invasive, catheter-based interventions performed through a tiny arterial puncture in the groin or wrist. They do not require abdominal incisions, open exposure of internal organs, or extensive surgical recovery.

Myth: Y-90 radioembolization makes the patient radioactive and unsafe to be around family members.
Reality: Yttrium-90 is a pure beta emitter with a tissue penetration depth averaging 2.5 mm. Radiation stays almost entirely within the patient's liver. Simple, temporary distance precautions for 3 to 7 days with pregnant women and small children are sufficient; patients do not pose a radiation hazard to the general public.

Myth: Chemotherapy from TACE causes widespread hair loss and severe nausea throughout the body.
Reality: Because chemotherapy is delivered directly into liver arterial branches and trapped inside the tumor with embolic agents, systemic drug absorption is low. High systemic toxicities like severe hair loss (alopecia) are rare compared to traditional intravenous chemotherapy.

Myth: Y-90 radioembolization can only be performed once in a lifetime.
Reality: Y-90 radioembolization can be safely repeated in different areas of the liver, or even in the same region if residual viable tumor persists, provided the cumulative radiation dose to normal liver and lung tissues remains within safe guideline limits (CIRSE Guidelines, 2021).

Myth: If a liver tumor does not shrink in physical size immediately after TACE or Y-90, the treatment failed.
Reality: Transarterial treatments work by causing internal cell death (necrosis) rather than immediate shrinkage. A successfully treated tumor may stay the same size or even transiently swell on imaging, but contrast-enhanced MRI or CT will reveal that blood flow inside the tumor has stopped, indicating successful control.

Myth: Patients with portal vein blood clots cannot undergo any transarterial treatment.
Reality: While main portal vein occlusion is an absolute contraindication for TACE due to the risk of total blood flow block, Y-90 radioembolization is safe and effective in patients with branch or segmental portal vein tumor thrombosis because its microspheres do not block macrovascular arterial blood flow (Salem et al., 2016).

17. Frequently Asked Questions

What is the main difference between TACE and Y-90 radioembolization?

TACE combines localized chemotherapy drugs with vascular occlusion to block blood flow and starve the tumor. Y-90 radioembolization delivers microscopic radioactive spheres that emit localized beta radiation directly into tumor tissue without completely blocking blood flow. TACE relies heavily on vascular blockage, whereas Y-90 functions primarily as internal radiation therapy.

Is TACE or Y-90 radioembolization painful?

The procedure itself is painless because the inside of blood vessels lacks pain receptors, and local anesthesia with sedation keeps patients comfortable. After TACE, patients frequently experience moderate abdominal pain for 24 to 48 hours due to tissue ischemia. Pain after Y-90 is typically much milder and easily controlled with oral pain medications.

How long will I need to stay in the hospital?

TACE usually requires a 1-night hospital stay for observation, IV hydration, and control of post-embolization symptoms. Y-90 radioembolization is frequently performed as an outpatient procedure or requires a brief overnight stay, allowing most patients to return home within 6 to 24 hours.

Why do I need a separate mapping procedure before Y-90 radioembolization?

The pre-Y-90 mapping procedure (angiography with Technetium-99m MAA) is critical for safety. It maps your liver's blood vessels, allows doctors to block vessels going to your stomach or intestines, measures how much blood shunts from your liver to your lungs, and allows physicists to calculate your exact personalized radiation dose.

Can TACE or Y-90 cure my liver cancer?

TACE and Y-90 are primarily considered disease-controlling therapies rather than standalone cures. However, they can effectively shrink tumors down to a size where curative treatments—such as surgical resection, thermal ablation, or liver transplantation—become possible. For many patients, these procedures provide long-term tumor control and extend survival.

How soon can I return to work and daily activities after treatment?

Most patients resume light daily activities within 3 to 5 days after the procedure. Return to full-time work and normal exercise typically occurs within 7 to 14 days, once post-procedure fatigue, mild nausea, and abdominal discomfort have resolved.

What is post-embolization syndrome?

Post-embolization syndrome (PES) is a temporary set of symptoms caused by tumor breakdown and tissue inflammation after arterial treatment. Symptoms include fatigue, low-grade fever, nausea, and right upper quadrant abdominal pain. PES typically peaks within 48 to 72 hours and resolves within 1 to 2 weeks with supportive care.

Will I lose my hair after chemoembolization (TACE)?

Hair loss is rare after TACE. Because chemotherapeutic medications are injected directly into liver arteries and trapped inside the tumor with embolic particles, very little drug enters the general bloodstream, avoiding major systemic side effects like widespread hair loss.

How many treatment sessions will I need?

The number of sessions depends on tumor size, location, and initial response. Single small tumors may require only one session. Multifocal tumors or large lesions involving both liver lobes may be treated over 2 to 4 planned sessions spaced 4 to 8 weeks apart.

Can I receive Y-90 or TACE if I have cirrhosis?

Yes, provided your cirrhosis is well-compensated (Child-Pugh Class A or early Class B). Patients with advanced, decompensated cirrhosis (Child-Pugh Class C, severe jaundice, or uncontrolled fluid accumulation) cannot safely receive transarterial therapies due to a high risk of acute liver failure.

What imaging tests are used to check if the treatment worked?

Follow-up imaging is performed 1 to 3 months post-procedure using multiphasic contrast-enhanced CT or contrast-enhanced liver MRI. Radiologists evaluate treatment success using mRECIST or LI-RADS criteria, looking for the disappearance of arterial blood flow inside the tumor rather than simple size changes.

What happens if the tumor starts growing again after treatment?

If follow-up scans show residual active tumor or new lesions, your multidisciplinary liver team will re-evaluate your case. Repeat TACE or Y-90 procedures, switching from TACE to Y-90, adding systemic immunotherapy, or evaluating for thermal ablation or surgery can all be considered if your liver function remains stable.